{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:02:22Z","timestamp":1786672942736,"version":"build-2736575974"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.00134","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:43:40Z","timestamp":1551159820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacogenomics of Multiple Sclerosis: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Keli","family":"Ho\u010devar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smiljana","family":"Risti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"B1","first-page":"700","article-title":"Multiple sclerosis genetics","volume-title":"Lancet Neurol.","author":"Sawcer","year":"2014"},{"key":"B2","first-page":"263","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume-title":"Lancet Neurol.","author":"Belbasis","year":"2015"},{"key":"B3","first-page":"1081","article-title":"Current developments in pharmacogenomics of multiple sclerosis","volume-title":"Cell Mol Neurobiol.","author":"Carlson","year":"2014"},{"key":"B4","first-page":"1976","article-title":"HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis","volume-title":"Neurology","author":"Fusco","year":"2001"},{"key":"B5","first-page":"344","article-title":"Defining the response to interferon-\u03b2 in relapsing-remitting multiple sclerosis patients","volume-title":"Ann Neurol.","author":"R\u00edo","year":"2006"},{"key":"B6","first-page":"679","article-title":"Comparative pharmacogenetics of multiple sclerosis: IFN-beta versus glatiramer acetate","volume-title":"Pharmacogenomics","author":"Kulakova","year":"2014"},{"key":"B7","first-page":"115","article-title":"A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity","volume-title":"Ann Neurol.","author":"Esposito","year":"2015"},{"key":"B8","first-page":"75","article-title":"Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting","volume-title":"Nat Rev Neurol.","author":"Tur","year":"2018"},{"key":"B9","first-page":"134","article-title":"Multiple sclerosis - a quiet revolution","volume-title":"Nat Rev Neurol.","author":"Ransohoff","year":"2015"},{"key":"B10","first-page":"103","article-title":"Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs","volume-title":"Pharmacogenet Genomics","author":"Tsareva","year":"2016"},{"key":"B11","first-page":"972","article-title":"Genome-wide scan of 500 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis","volume-title":"Arch Neurol.","author":"Comabella","year":"2009"},{"key":"B12","first-page":"33","article-title":"Balancing early aggression against risk of progression in multiple sclerosis","volume-title":"Can J Neurol Sci.","author":"Duquette","year":"2015"},{"key":"B13","first-page":"D183","article-title":"PANTHER version 11: expanded annotation data from gene ontology and reactome pathways, and data analysis tool enhancements","volume-title":"Nucleic Acids Res.","author":"Mi","year":"2017"},{"key":"B14","first-page":"2","article-title":"Interferon beta and glatiramer acetate therapy","volume-title":"Neurotherapeutics","author":"McGraw","year":"2013"},{"key":"B15","first-page":"S3","article-title":"Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis","volume-title":"Neurology","author":"Dhib-Jalbut","year":"2002"},{"key":"B16","first-page":"194","article-title":"The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta","volume-title":"J Neuroimmunol.","author":"Villoslada","year":"2002"},{"key":"B17","first-page":"391","article-title":"HLA class II and response to interferon-beta in multiple sclerosis","volume-title":"Acta Neurol Scand","author":"Fern\u00e1ndez","year":"2005"},{"key":"B18","first-page":"116","article-title":"HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis","volume-title":"J Neuroimmunol.","author":"Comabella","year":"2009"},{"key":"B19","first-page":"168","article-title":"Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments","volume-title":"J Neuroimmunol.","author":"Gross","year":"2011"},{"key":"B20","first-page":"37","article-title":"HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients","volume-title":"J Neurol Sci.","author":"Samadzadeh","year":"2015"},{"key":"B21","first-page":"147","article-title":"Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis","volume-title":"Genes Immun.","author":"Sriram","year":"2003"},{"key":"B22","first-page":"165","article-title":"IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response","volume-title":"J Neuroimmunol.","author":"Leyva","year":"2005"},{"key":"B23","first-page":"132","article-title":"Apolipoprotein alleles and the response to interferon-\u03b2-1b in multiple sclerosis","volume-title":"Eur Neurol.","author":"Carmona","year":"2011"},{"key":"B24","first-page":"137","article-title":"Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis","volume-title":"Neurol (English Ed","author":"Guerrero","year":"2011"},{"key":"B25","first-page":"40","article-title":"Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection","volume-title":"Genes Immun.","author":"Vandenbroeck","year":"2011"},{"key":"B26","first-page":"268","article-title":"Prediction of response to interferon therapy in multiple sclerosis","volume-title":"Acta Neurol Scand.","author":"Sellebjerg","year":"2014"},{"key":"B27","first-page":"1507","article-title":"NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients","volume-title":"Mult Scler J.","author":"Malhotra","year":"2018"},{"key":"B28","first-page":"644","article-title":"NLRP3 inflammasome is associated with the response to IFN-beta in patients with multiple sclerosis","volume-title":"Brain","author":"Malhotra","year":"2015"},{"key":"B29","first-page":"236","article-title":"Pharmacogenetics of MXA SNPs in interferon-\u03b2 treated multiple sclerosis patients","volume-title":"J Neuroimmunol.","author":"Weinstock-Guttman","year":"2007"},{"key":"B30","first-page":"913","article-title":"Glypican 5 is an interferon-beta response gene: a replication study","volume-title":"Mult Scler","author":"C\u00e9nit","year":"2009"},{"key":"B31","first-page":"101","article-title":"IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis","volume-title":"J Neuroimmunol.","author":"Malhotra","year":"2011"},{"key":"B32","first-page":"635","article-title":"Pharmacogenomics of responsiveness to interferon IFN-\u03b2 treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes","volume-title":"Clin Pharmacol Ther.","author":"Cunningham","year":"2005"},{"key":"B33","first-page":"1093","article-title":"Myxovirus resistance protein A (MxA) polymorphism is associated with IFN\u03b2 response in Iranian multiple sclerosis patients","volume-title":"Neurol Sci.","author":"Sayad","year":"2017"},{"key":"B34","first-page":"1689","article-title":"Allelic combinations of immune-response genes as possible composite markers of IFN-\u03b2 efficacy in multiple sclerosis patients","volume-title":"Pharmacogenomics","author":"Kulakova","year":"2012"},{"key":"B35","first-page":"727","article-title":"Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-\u03b2 therapy","volume-title":"IUBMB Life","author":"Karam","year":"2016"},{"key":"B36","first-page":"466","article-title":"Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferon\u03b2 therapy in multiple sclerosis","volume-title":"Genes Immun.","author":"Vosslamber","year":"2011"},{"key":"B37","first-page":"337","article-title":"Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis","volume-title":"Arch Neurol.","author":"Byun","year":"2008"},{"key":"B38","first-page":"e154","article-title":"Pharmacogenomic study in patients with multiple sclerosis: responders and nonresponders to IFN-\u03b2","volume-title":"Neurol Neuroimmunol Neuroinflamm.","author":"Bustamante","year":"2015"},{"key":"B39","first-page":"1177","article-title":"Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients","volume-title":"Pharmacogenomics","author":"O'Doherty","year":"2009"},{"key":"B40","first-page":"171","article-title":"IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis","volume-title":"Eur J Neurol.","author":"Wergeland","year":"2005"},{"key":"B41","first-page":"232","article-title":"Angiotensin-converting enzyme insertion\/deletion gene polymorphism and interferon-\u03b2 treatment response in multiple sclerosis patients","volume-title":"Pharmacogenet Genomics","author":"Risti\u0107","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.22074\/cellj.2015.505","article-title":"Association of CD58 polymorphism with multiple sclerosis and response to interferon \u00df therapy in a subset of Iranian population","volume":"16","author":"Torbati","year":"","journal-title":"Cell J."},{"key":"B43","first-page":"1390","article-title":"Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-\u03b2 treatment","volume-title":"Eur J Neurol.","author":"Malhotra","year":"2013"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e62540","DOI":"10.1371\/journal.pone.0062540","article-title":"Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients","volume":"8","author":"L\u00f3pez-G\u00f3mez","year":"2013","journal-title":"PLoS O NE"},{"key":"B45","first-page":"196","article-title":"An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients","volume-title":"J Neuroimmunol.","author":"Mart\u00ednez","year":"2006"},{"key":"B46","first-page":"513","article-title":"CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment","volume-title":"Mult Scler.","author":"Alvarez-Lafuente","year":"2011"},{"key":"B47","first-page":"489","article-title":"HLA genes as modifiers of response to IFN-beta-1a therapy in relapsing-remitting multiple sclerosis","volume-title":"Pharmacogenomics","author":"Mazdeh","year":"2016"},{"key":"B48","first-page":"238","article-title":"Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-\u03b2 therapy in multiple sclerosis patients","volume-title":"Pharmacogenomics J.","author":"Weber","year":"2012"},{"key":"B49","first-page":"312","article-title":"Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study","volume-title":"Pharmacogenomics J.","author":"Mahurkar","year":"2017"},{"key":"B50","first-page":"84","article-title":"Pharmacogenetic study of long-term response to interferon-beta treatment in multiple sclerosis","volume-title":"Pharmacogenomics J.","author":"Clarelli","year":"2017"},{"key":"B51","first-page":"84","article-title":"Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition","volume-title":"J Neuroimmunol.","author":"Hasson","year":"2016"},{"key":"B52","first-page":"340","article-title":"HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis","volume-title":"Mult Scler Relat Disord.","author":"Dhib-Jalbut","year":"2013"},{"key":"B53","first-page":"1563","article-title":"Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci","volume-title":"Pharmacogenomics","author":"Kulakova","year":"2017"},{"key":"B54","first-page":"657","article-title":"Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers","volume-title":"Pharmacogenet Genomics","author":"Grossman","year":"2007"},{"key":"B55","first-page":"43","article-title":"Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients","volume-title":"Pharmacogenomics","author":"Tsareva","year":"2012"},{"key":"B56","first-page":"1","article-title":"A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis","volume-title":"Genome Med.","author":"Ross","year":"2017"},{"key":"B57","first-page":"1359","article-title":"Drugs approved for the treatment of multiple sclerosis: review of their safety profile","volume-title":"Expert Opin Drug Saf.","author":"Auricchio","year":"2017"},{"key":"B58","first-page":"2517","article-title":"ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis","volume-title":"Brain","author":"Cotte","year":"2009"},{"key":"B59","first-page":"277","article-title":"Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis","volume-title":"J Neuroimmunol.","author":"Grey","year":"2015"},{"key":"B60","first-page":"586","article-title":"Possible implication of GSTP1 and NQO1 polymorphisms on natalizumab response in multiple sclerosis","volume-title":"Ann Clin Lab Sci.","author":"Alexoudi","year":"2016"},{"key":"B61","first-page":"414","article-title":"Pharmacogenomics knowledge for personlized medicine","volume-title":"Clin Pharmacol Ther.","author":"Whirl-Carrillo","year":"2012"},{"key":"B62","first-page":"II15","article-title":"Immunogenicity of interferon beta: differences among products","volume-title":"J Neurol.","author":"Bertolotto","year":"2004"},{"key":"B63","first-page":"835","article-title":"Interferon \u03b2-1b-neutralizing antibodies 5 years after clinically isolated syndrome","volume-title":"Neurology","author":"Hartung","year":"2011"},{"key":"B64","first-page":"54","article-title":"Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study","volume-title":"BMC Neurol.","author":"Sbardella","year":"2009"},{"key":"B65","first-page":"219","article-title":"HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-\u03b2 therapy in multiple sclerosis","volume-title":"Am J Hum Genet.","author":"Hoffmann","year":"2008"},{"key":"B66","first-page":"480","article-title":"Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis","volume-title":"Arch Neurol.","author":"Buck","year":"2011"},{"key":"B67","first-page":"395","article-title":"HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-\u03b2 therapy in multiple sclerosis","volume-title":"J Med Genet.","author":"N\u00fa\u00f1ez","year":"2014"},{"key":"B68","first-page":"e90479","article-title":"Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis","volume-title":"PLoS ONE","author":"Link","year":"2014"},{"key":"B69","first-page":"e1927","article-title":"Pharmacogenomics of interferon-\u03b2 therapy in multiple sclerosis: baseline IFN signature determines phamacological differences between patients","volume-title":"PLoS ONE","author":"van Baarsen","year":"2008"},{"key":"B70","first-page":"3353","article-title":"A type i interferon signature in monocytes is associated with poor response to interferon-\u03b2 in multiple sclerosis","volume-title":"Brain","author":"Comabella","year":"2009"},{"key":"B71","first-page":"423","article-title":"Sieving treatment biomarkers from blood gene-expression profiles: A pharmacogenomic update on two types of multiple sclerosis therapy","volume-title":"Pharmacogenomics","author":"Goertsches","year":"2011"},{"key":"B72","first-page":"e19262","article-title":"Excessive biologic response to IFN\u03b2 is associated with poor treatment response in patients with multiple sclerosis","volume-title":"PLoS ONE","author":"Rudick","year":"2011"},{"key":"B73","first-page":"675","article-title":"Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season","volume-title":"Mult Scler J.","author":"Parnell","year":"2014"},{"key":"B74","first-page":"1693","article-title":"Immunophenotype and transcriptome profile of patients with multiple sclerosis treated with fingolimod: Setting up a model for prediction of response in a 2-year translational study","volume-title":"Front Immunol.","author":"Moreno-Torres","year":"2018"},{"key":"B75","first-page":"e29648","article-title":"Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis","volume-title":"PLoS ONE","author":"Hecker","year":"2011"},{"key":"B76","first-page":"34","article-title":"A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients","volume-title":"J Neuroimmunol.","author":"Martire","year":"2016"},{"key":"B77","first-page":"3726","article-title":"Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro","volume-title":"Eur J Immunol.","author":"Beck","year":"2001"},{"key":"B78","first-page":"553","article-title":"Predicting responders to therapies for multiple sclerosis","volume-title":"Nat Rev Neurol.","author":"R\u00edo","year":"2009"},{"key":"B79","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1126\/science.1217876","article-title":"NIH Public Access","volume":"337","author":"Nelson","year":"2015"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T05:43:51Z","timestamp":1551159831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.00134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":79,"alternative-id":["10.3389\/fneur.2019.00134"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.00134","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"article-number":"134"}}